There are 36 signatories to the joint procurement agreement participating in this procurement, including all EU countries, EEA countries, the United Kingdom, as well as six candidate and potential candidate countries (Albania, Northern Macedonia, Montenegro, Serbia, Kosovo * and Bosnia and Herzegovina).

All participating countries can now place their Veklury orders directly. At this stage, Veklury is the only medicine that has a conditional marketing authorization for the treatment of patients with COVID-19 who need oxygen.

“Today we have provided access to remdesivir to treat up to 500,000 patients who need this medicine. We are doing everything we can to ensure the availability of safe and effective therapies against COVID-19. Through joint procurement at EU level, we enable countries across Europe to join forces and have access to vital equipment and medicines. We are always stronger together, and this acquisition represents European solidarity in action against COVID-19, “said Stella Kyriakides, Commissioner for Health and Food Safety.

The signing of this joint procurement framework agreement comes with the Commission’s contract with Gilead to provide 33,380 treatment courses with Veklury, which have been distributed throughout the EU and the UK since August. This contract is worth a total of EUR 70 million.

“Treatment belts purchased with ESI funds have helped meet immediate needs from August to October to ensure that critically ill patients receive the necessary treatment. The medication was delivered in several installments. The joint procurement contract will now ensure that the respective countries will continue to benefit from an uninterrupted supply with Veklury if they decide to purchase the product “, states the European Commission.